In the Era of ADC, HER2 is No Longer Limited to ‘Positive’ and ‘Negative’
In the world of oncology, HER2 (human epidermal growth factor receptor 2) used to represent a simple boundary—positive meant eligibility for treatment; negative meant no access to targeted therapy.. However, with the advent of antibody-drug conjugates (ADCs), this boundary has begun to blur. This article published in Gynecologic Oncology illustrates that:HER2 is no longer a … Read more